BDC Launches $150 Million Life Sciences Venture Fund to Address Early-Stage Funding Gap in Canada
核心洞察
The Business Development Bank of Canada (搜索) announced a $150 million Life Sciences Venture Fund targeting early-stage seed and Series A companies in therapeutics and medical technologies (搜索).
The fund aims to address significant financing gaps in Canada's life sciences sector, which contributes $18.3 billion annually and supports over 135,000 specialized jobs.
Parimal Nathwani, a seasoned life sciences leader with over 20 years of experience, has been appointed as Managing Partner to lead the new fund.
The Business Development Bank of Canada (搜索) (BDC) announced the launch of its $150 million Life Sciences Venture Fund on April 9, 2026, designed to support the next generation of Canadian companies in the sector. The fund represents a strategic initiative to address critical financing gaps that have hindered early-stage life sciences companies from advancing from laboratory research to market commercialization.
Addressing Critical Funding Gaps
The new fund will provide patient capital to early-stage seed and Series A companies, focusing specifically on therapeutic products (搜索) and medical technologies (搜索)—two sectors where Canada demonstrates the strongest competitive advantages. Despite the life sciences sector showing the strongest 10-year venture capital returns in Canada, significant financing gaps persist, particularly at the earliest stages of company development.
"Life sciences is one of our most innovative sectors, yet that success is at risk as early-stage companies continue to be left behind by investors," said Geneviève Bouthillier, Executive Vice President, BDC Capital (搜索). "It's a risk we can no longer ignore—especially at a time when Canada needs more champions to build our own economic sovereignty right here at home."
Economic Impact and Strategic Importance
Life sciences represent a major economic driver for Canada, contributing $18.3 billion annually and representing 0.8% of the country's GDP while supporting more than 135,000 specialized jobs. The sector's significance extends beyond economic metrics, as it is directly tied to Canada's economic sovereignty, national security, and ability to support essential health advances for Canadians.
The fund aims to complement the existing market by providing a new source of Canadian capital, helping entrepreneurs bring innovative health solutions to market while retaining scientific talent within Canada to strengthen the country's competitive position.
Leadership and Vision
BDC has appointed Parimal Nathwani as Managing Partner of the Life Sciences Venture Fund. Nathwani brings more than 20 years of experience in building and scaling biotechnology and medical technology companies, with recognized expertise in strategic vision, execution, scientific models, and commercialization challenges.
"Canada has world-class talent and a strong life sciences innovation base," said Nathwani. "But with a significant early-stage funding gap, combined with long development cycles and demanding scientific validation, the needs are pressing. By supporting early-stage companies in therapeutics and medical devices, we aim to turn Canadian research and intellectual property into globally competitive businesses that improve human health, create high-quality jobs, generate economic impact and strengthen Canada's innovation ecosystem."
Reducing Foreign Investment Dependence
The fund launch addresses concerns about Canada's over-reliance on foreign investment in the life sciences sector, which has weakened the country's capacity to build and retain globally competitive companies domestically. Bouthillier emphasized that the $150 million announcement represents "a clear statement that Canada intends to lead from within in life sciences."
The initiative aligns with BDC's broader mission as Canada's development bank to support entrepreneurs who don't fit traditional investment molds and help develop underserved markets to unlock economic potential. The fund is expected to play a crucial role in transforming Canadian research and intellectual property into globally competitive businesses while strengthening the country's innovation ecosystem.